Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US panel gives mixed vote to Protein Sciences' cell-based flu vaccine FluBlok

This article was originally published in Scrip

Executive Summary

Protein Sciences' novel trivalent seasonal influenza vaccine FluBlok (purified recombinant influenza haemagglutinin) is effective in subjects up to age of 49 years but not in older populations, and data do not support the cell-based vaccine's safety in all adults, the US FDA's experts have said.

You may also be interested in...



Confirmatory Trial Worries Clouded Tazverik’s Accelerated Approval

Given the rarity of epithelioid sarcoma, ‘the possibility exists that this trial will not be completed,’ Division of Oncology 3 acting director Steven Lemery said in recommending approval; confirmatory trial is not expected to complete until 2029, and FDA reviewers suggest it may be underpowered to show an effect on progression-free survival. (Part 2 of our Drug Review Profile on the product.)

Tazverik Clinical Development Timeline

Chronicle of the development and review of Epizyme’s epithelioid sarcoma treatment tazemetostat.

Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns

US FDA reviewers recommended against accelerated approval of Epizyme’s tazemetostat for epithelioid sarcoma, finding the modest overall response rates were not substantial evidence of an improvement over available therapies; they were overruled by senior oncology review staff, who cited a unanimous ODAC endorsement and the regulatory flexibility encouraged for rare diseases.

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel